Eli Lilly Slumps 3.3% as Merck Gains 2.2% on Healthcare Moves
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
eli-lillymerck
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.
Eli Lilly (LLY) shares declined 3.29% to trade at $1,180.16 as of 13:17 UTC today, contrasting with a 2.20% gain for Merck (MRK) to $135.84. This movement occurred amid a week of notable healthcare headlines focusing on these pharmaceutical giants and telehealth provider Hims & Hers Health. The intraday range for Lilly spanned from $1,171.20 to $1,199.00, indicating significant volatility during the session, while Merck traded between $133.40 and $135.97. Market participants assessed company-specific catalysts against a broader sector backdrop.
Eli Lilly's stock has been a standout performer in the healthcare sector, driven by dominant commercial positioning for its GLP-1 drugs Mounjaro and Zepbound. The stock had gained approximately 58% year-to-date prior to this pullback, making it one of the best-performing large-cap pharmaceutical equities. Merck's recent performance has also been strong, buoyed by strong Keytruda sales and successful oncology pipeline advancements.
The current macro environment features a 10-year Treasury yield near 4.25%, providing a stable backdrop for growth stock valuations. Healthcare sector performance has diverged from the broader S&P 500 index, which has gained approximately 8% year-to-date. This divergence reflects investor selectivity between defensive value plays and growth-oriented pharmaceutical names.
Recent catalyst chains include quarterly earnings reports from major healthcare providers and updated prescription data for weight loss medications. The FDA's drug approval calendar remains active through August, with several priority review decisions pending. Insurance coverage expansions for telehealth services have also influenced sector sentiment.
Eli Lilly's $1,180.16 price represents a decline of $40.16 from the previous close. The 3.29% single-day drop marks one of the stock's more significant daily moves in August, though it remains well above its 50-day moving average near $1,050. Merck's gain of $2.92 brings its market capitalization to approximately $344 billion, compared to Lilly's $670 billion valuation.
The healthcare sector overall has shown mixed performance, with the XLV Health Care Select Sector SPDR Fund declining 0.4% on the session. Biotechnology stocks as measured by the XBI ETF have gained 0.8%, indicating divergent momentum between established pharmaceuticals and emerging biotech names.
Trading volume data shows elevated activity for both stocks, with Lilly volume approximately 25% above its 30-day average and Merck volume 15% above average. Options flow indicates increased put buying protection on Lilly alongside call buying momentum for Merck. The volatility skew for Lilly options has shifted toward puts, suggesting heightened near-term concern among options traders.
Implied volatility levels for both stocks remain within historical ranges, with Lilly's 30-day implied volatility at 28% and Merck's at 22%. The price-to-earnings ratio disparity remains substantial, with Lilly trading at 88 times forward earnings compared to Merck's 15 times multiple. This valuation gap has prompted some profit-taking in high-multiple names amid sector rotation.
The divergent moves between these pharmaceutical leaders signal ongoing sector rotation rather than broad healthcare weakness. Companies with exposure to GLP-1 therapeutics, including Novo Nordisk and Zealand Pharma, showed modest declines alongside Lilly. Conversely, traditional pharmaceutical names with strong dividend yields, such as Johnson & Johnson and AbbVie, traded higher alongside Merck.
Second-order effects include pressure on medical device companies that provide weight management solutions, including Medtronic and Boston Scientific. These names declined 1-2% on the session as investors reassessed the competitive threat from pharmaceutical weight loss solutions. Telehealth providers including Teladoc and Amwell showed mixed performance amid the Hims & Hers Health headlines.
A counter-argument suggests that Lilly's decline represents routine profit-taking rather than fundamental deterioration. The stock remains up significantly year-to-date, and pullbacks have consistently found buyer support near the $1,150 level. Options market positioning indicates more hedge fund activity than fundamental investor selling.
Flow data shows institutional buyers accumulating Merck shares while taking profits on Lilly positions. Sector exchange-traded fund flows have been neutral overall, suggesting the moves represent internal rotation rather than sector-wide redemption pressure. Credit spreads for both companies remain tight, indicating no fundamental credit concern behind the equity moves.
The August 20 FDA advisory committee meeting on a new obesity treatment will provide the next catalyst for weight loss drug stocks. September 5 marks the next important data readout for Lilly's Alzheimer's candidate donanemab, with regulatory approval decisions expected in the fourth quarter. Merck's Keytruda combination therapy data readouts are scheduled for September 12 at the European Society for Medical Oncology conference.
Technical levels to watch for Lilly include support at $1,150, corresponding to the 21-day moving average, and resistance at the recent high of $1,210. Merck faces resistance at the $137 level, which has contained advances since June, with support at the 50-day moving average near $132.50.
Healthcare services utilization data due August 22 will provide insight into patient demand patterns following recent insurance changes. The Centers for Medicare & Medicaid Services will announce 2027 payment rules for Medicare Advantage plans on August 30, potentially affecting healthcare services and managed care stocks.
Eli Lilly shares declined 3.29% amid broader profit-taking in high-valuation pharmaceutical names that have outperformed significantly year-to-date. The stock had gained approximately 58% in 2026 prior to this pullback, creating natural profit-taking pressure. Options market activity indicated increased hedging activity rather than fundamental selling, with no company-specific news driving the decline.
Merck trades at a forward price-to-earnings ratio of 15 compared to Eli Lilly's 88 multiple, reflecting different growth expectations and business models. Merck's valuation includes its established oncology franchise and dividend yield, while Lilly's premium valuation reflects dominant positioning in GLP-1 therapeutics for diabetes and obesity. Both companies maintain strong balance sheets with investment-grade credit ratings.
The divergence between these pharmaceutical leaders suggests ongoing sector rotation rather than broad weakness. Investors are differentiating between growth-oriented therapeutic franchises and value-oriented established businesses. Sector performance may remain bifurcated based on individual company pipelines rather than moving in unison, requiring more selective investment approaches within healthcare.
Healthcare sector rotation favors value pharmaceutical names over growth counterparts amid valuation reassessment.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
AiX is our free MetaTrader 4 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.